The Conversation (0)
AntriaBio, Inc. (OTCMKTS:ANTB) has entered into an agreement for the lease of primary manufacturing and laboratory facility in Louisville, Colorado for research and manufacture of microspheres for its lead product candidate AB101, a once-weekly basal insulin for the treatment of diabetes.
AntriaBio, Inc. (OTCMKTS:ANTB) has entered into an agreement for the lease of primary manufacturing and laboratory facility in Louisville, Colorado for research and manufacture of microspheres for its lead product candidate AB101, a once-weekly basal insulin for the treatment of diabetes.
As quoted in the press release:
Located just outside of Boulder, Colorado, the address of the new facility is 1450 Infinite Drive, Louisville, Colorado and comprised of approximately 27,000 square feet including separate laboratory space, manufacturing suites and office space. State-of-the-art laboratory and manufacturing equipment acquired by AntriaBio through the acquisition of PR Pharmaceuticals, Inc.’s intellectual property and assets in 2013, will be moved into the new facility next week and will be used for AB101, as well as other potential pipeline candidates. The Company’s corporate headquarters will continue to be located in Silicon Valley in Menlo Park, California.
Click here to read the AntriaBio (OTCMKTS:ANTB) press release
